Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

PRODIGE 113 (FFCD 2314) – REWENEC – 01 STUDY Randomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic co… Not authorised

2024-519922-19-00 Neuroendocrine carcinoma of gastro-enteropancreatic or 4
A phase I/II trial of ABTL0812 in children with relapsed/refractory neuroblastoma and other solid tumours Not authorised

2023-504246-64-00 Relapsed/refractory neuroblastoma and other solid tumou 9
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence Not authorised

2024-515609-25-00 Glioblastoma 4
A Phase I Study of RO7589831 in Participants with Advanced Solid Tumors Not authorised

2023-503170-20-00 Advanced solid tumors 1
Clinical trial of MK-7648A in adults and children with skin cancer Not authorised

2022-501417-31-00 High-risk Resected Melanoma 5
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inh… Not authorised

2023-505311-20-00 Metastatic Non-Small Cell Lung Cancer 5
ExplOratory, Phase 0 Study to assess biodisTribution and PosItron EMission Tomography (PET) Imaging kinetics of [64Cu]Cu-PSMA-R2 in metaStat… Not authorised

2023-508473-86-00 metastatic prostate cancer 3
EORTC 2237-BCG-QLG: Improvement of Quality of Life through supportive treatments for Endocrine Therapy – related symptoms in patients with e… Not authorised

2024-513442-10-00 ER positive HER2 negative breast cancer stages I-II 5
A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vi… Not authorised

2024-515642-17-00 non-segmental vitiligo 4
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) - targeting, Bif… Not authorised

2023-505334-10-00 Unresectable, Locally Advanced, or Metastatic Solid Tum 7
An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Not authorised

2022-501463-40-00 Locally Advanced or Metastatic Cholangiocarcinoma 5
QIMPD SUBMISSION ONLY Not authorised

2023-509510-11-00 NA 5
Clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas Not authorised

2024-514827-40-00 Patients with advanced soft-tissue sarcoma (leiomyosarc 9
18F-FDG versus 68Ga-FAPI-46 as PET tracer in ER-positive breast cancer - a pilot study Not authorised

2023-508066-15-00 Hormone-positive breast cancer 4
A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based the… Not authorised

2022-500721-32-00 AML and MDS patients failing or being refractory to hyp 4
Evaluation of the safety and efficacy of the drug AL8326 in the post-first treatment of small cell lung cancer. Not authorised

2023-509067-24-00 Small Cell Lung Cancer (SCLC) patients who need ≥2nd li 4
Phase 1b/2a Study to Evaluate Alnuctamab in Combination with Mezigdomide in Relapsed and/or Refractory Multiple Myeloma. Not authorised

2023-504367-16-00 Relapsed and/or Refractory Multiple Myeloma 4
Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT. Not authorised

2024-517002-28-00 graft-versus-host disease 3
A clinical study using a radioactive imaging agent with PET-CT to detect neuroendocrine tumors Not authorised

2025-524050-34-01 Neoplasms 5
Early detection of triple negative breast cancer relapse (CUPCAKE) Not authorised

2022-501562-22-00 Triple-negative breast cancer (TNBC) patients at high r 4
Targeting inflammation to reduce 90-day and 1-year postoperative severe morbidity in patients with unfavorable inflammatory profile undergoi… Not authorised

2024-515333-14-00 Patients scheduled for major surgery for oncologic indi 5
A trial to learn how ceralasertib affects the way certain medications move throughout the body over time and how safe it is to use ceralaser… Not authorised

2024-516611-24-00 Advanced solid tumour 3
Safety, tolerability, and efficacy of mFOLFIRINOX ±BNT321 as adjuvant therapy following curative resection in patients with pancreatic adeno… Not authorised

2023-506014-47-00 Resected (R0 or R1) pancreatic ductal adenocarcinoma 9
CELL-BASED IMMUNOTHERAPY FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER STAGES II AND III Not authorised

2023-506019-16-01 TRIPLE NEGATIVE BREAST CANCER 7